Highlighting the dual targeting of mTOR and AKT as an efficient therapy approach of HCC is of great clinical interest, since MK-2206 is already being tested in clinical trials and reported to be well tolerated[49,50]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.